Turner Syndrome Clinical Trial
Official title:
Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome
Verified date | May 2021 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale: Infertility due is a major concern for girls with Turner syndrome (TS) and their parents. Physicians are often asked about possible options to preserve their fertility. However, despite some experimental case reports, clear evidence for fertility preservation in these girls is lacking and many questions remain. Without evidence on the effectiveness of fertility preservation it cannot routinely be offered to girls with TS. Objective: To investigate the occurrence of live birth in women with TS after ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. Study design: A national multicentre exploratory intervention study Study population: Girls diagnosed with Turner Syndrome, aged 2-18 years. Intervention: Ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. In order to obtain the ovarian tissue for cryopreservation, all girls must undergo a laparoscopy under general anaesthesia which will be performed in academic/university clinics with paediatric surgery. During the laparoscopic intervention, a unilateral oophorectomy will be performed, thereby leaving the other ovary intact for hormone production, ovulation, spontaneous pregnancies and as an auto transplantation site for cryopreserved-thawed ovarian cortical tissue later on. Furthermore, a small sample of the ovarian cortex will be used to assess the oocyte quality and genetics (e.g. the presence of germ line mosaicism). Oocytes will be karyotyped by using Fluorescence in situ hybridization (FISH). Karyotypic and hormonal data will be collected once at the yearly clinical visit at the paediatric-endocrinologist. Therefore, a buccal swab and one extra blood sample will be taken and evaluated during the routine laboratory evaluation. In the future, auto transplantation of frozen-thawed ovarian cortex strips will be performed.
Status | Active, not recruiting |
Enrollment | 106 |
Est. completion date | November 1, 2071 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 2 Years to 18 Years |
Eligibility | Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Girls and young females with classic Turner (i.e. 45X monosomy) or Turner variants (e.g. 45X / 46XX mosaicism, ring X mosaicism, isochromosome X), - Aged 2 through 18 years, - who completed the diagnostic work up phase of TS including routine cardiac screening*, - whose agreement to participate in this study has been signed by the parents (girls 2-11 years old), - whose agreement to participate in this study has been signed by the patient and her parents (girls 12-17 years old), - whose agreement to participate in this study has been signed by the patient (adolescents of 18 years old). Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Contra-indications for laparoscopic unilateral oophorectomy under general anaesthesia (e.g. severe cardiovascular comorbidity and/or BMI >40 kg/m2)*, - Contra-indications for cryopreservation (i.e. active HIV, hepatitis-B or hepatitis-C infection) - Based on the international Cincinnati Turner Guideline consensus Meeting, July 2016 and consultation of Dutch cardiologists, paediatric-cardiologists and anaesthesists between 2016-2017 there are no absolute cardiovascular contra-indications for surgical intervention and/or pregnancy. Advice against surgical intervention and/or pregnancy should be based on the patient-specific cardiovascular risk profile. The 2% mortality risk due to acute aortic dissection is based on one survey and literature review study that reported the outcomes of 101 pregnancies in patients with TS after oocyte donation. Only 50% of the patients were screened by a cardiologist before entering the oocyte donation programme. Therefore, all girls who want to participate in this study should have completed the diagnostic work up phase of TS including routine cardiac screening and will be screened by a paediatric anaesthesist. Exclusion will be based on the patient specific risk profile. See: References. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboud university medical center. Department Obstetrics & Gynaecology. | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Netherlands,
Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70. doi: 10.1530/EJE-17-0430. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Study participation rate | The willingness of girls with TS to perform a unilateral oophorectomy for fertility preservation (i.e. the study participation rate) | Up to 3 years after inclusion | |
Other | Eligible participants | The number of eligible participants | Up to 3 years after inclusion | |
Other | Age | The age of the participant | Up to 3 years after inclusion | |
Other | Buccal cells versus peripheral lymphocytes | The incidence of somatic mosaicism (i.e. buccal cells versus peripheral lymphocytes) | Up to 3 years after inclusion | |
Other | Ovarian cells versus peripheral lymphocytes | The incidence of germ cell mosaicism (i.e. ovarian cells versus peripheral lymphocytes and buccal cells) | Up to 3 years after inclusion | |
Other | Serum hormone levels | Serum hormone levels (i.e. FSH, Luteinizing hormone (LH), AMH, E2, inhibin B) | Up to 3 years after inclusion | |
Other | Complication rate | The number of complications related to the laparoscopic procedure | Up to 1 year after the laparoscopic procedure | |
Other | Influence of laparoscopic oophorectomy on puberty and/or menarche | The incidence of puberty and/or menarche after laparoscopic oophorectomy | Up to 10 years after the laparoscopic procedure | |
Other | Incidence of spontaneous pregnancies | The incidence of spontaneous pregnancies after laparoscopic oophorectomy | Up to 45 years after the laparoscopic procedure | |
Other | Restoration of ovarian function after auto transplantation of ovarian tissue | The incidence of menstruation cycle recovery after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Other | Pregnancies after auto transplantation of ovarian tissue | The incidence of pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Other | Ongoing pregnancies after auto transplantation of ovarian tissue | The incidence of ongoing pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years and 3 months after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Other | Miscarriages after auto transplantation of ovarian tissue | The number of miscarriages after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Other | Time to pregnancy after auto transplantation of ovarian tissue | Time to pregnancy after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Other | Time to live birth after auto transplantation of ovarian tissue | Time to live birth after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue | |
Primary | Live birth ratio (LBR) (main outcome) | • Live birth after auto transplantation of cryopreserved-thawed ovarian cortical tissue (i.e. live birth rate or LBR) | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. | |
Primary | Number of primordial follicles (proximate) | The number of primordial follicles found in the ovarian tissue | Within 1 month after ovarian tissue cryopreservation | |
Secondary | Patient's age versus LBR | The association between patient's age at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. | |
Secondary | Patient's genotype versus LBR | The association between patient's genotype and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. | |
Secondary | Patient's Anti-Müllerian hormone (AMH) level versus LBR | The association between patient's AMH level at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. | |
Secondary | Patient's Follicle-stimulating hormone (FSH) level versus LBR | The association between patient's FSH level at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
Completed |
NCT01419249 -
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
|
Phase 4 | |
Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
Recruiting |
NCT04948658 -
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
|
||
Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT02787486 -
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
|
||
Completed |
NCT00877942 -
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
|
N/A | |
Completed |
NCT00825617 -
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
|
N/A | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
Terminated |
NCT00419107 -
Beta Cell Function in Women With Turner Syndrome
|
N/A | |
Active, not recruiting |
NCT00625001 -
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
|
N/A | |
Completed |
NCT00029159 -
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
|
Phase 3 | |
Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT00471731 -
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
|
N/A | |
Completed |
NCT00256126 -
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
|
Phase 4 | |
Completed |
NCT03181230 -
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
|